ClinicalTrials.gg
CompletedNCT06065540REIMAGINE 2Updated Jul 8, 2026

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

A Phase 3 interventional study of Cagrilintide and Semaglutide in Type 2 Diabetes Mellitus, sponsored by Novo Nordisk A/S. Completed at 405 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,734
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.

Enrollment
Largest of 15
2,734 · median 274
Started
2023
with 1 other
Phase 3
10 of 15
3 open now
Registered
3rd of 15
by date
Lead sponsor
15 of 15
Novo Nordisk A/S

Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 2 that started in 2023, is one of 10 in phase 3, and was the 3rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (sex at birth).
  • Age 18 years or above at the time of signing the .
  • Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening.
  • Stable daily dose(s) greater than or equal to 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors.
  • (HbA1c) 7.0-10.5 percent (53-91 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening.
  • (BMI) greater than or equal to 25 kilogram per square metre ( kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.

Exclusion criteria

Exclusion Criteria:

  • Renal impairment with estimated (eGFR) less than 30 milliliters per minute per 1.73 square metre (mL/min/1.73 m\^2) as determined by central laboratory at screening.
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,734 participants (actual)

Study arms

  • Experimental
    CagriSema Dose 1

    Participants will receive once-weekly subcutaneous (s.c) injections of cagrilintide dose 1 and semaglutide dose 1 for 68 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Experimental
    CagriSema Dose 2

    Participants will receive once-weekly s.c injections of cagrilintide dose 2 and semaglutide dose 2 for 68 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Active comparator
    Semaglutide Dose 1

    Participants will receive once-weekly s.c injection of semaglutide dose 1 for 68 weeks.

    Drug: Semaglutide

  • Active comparator
    Semaglutide Dose 2

    Participants will receive once-weekly s.c injection of semaglutide dose 2 for 68 weeks.

    Drug: Semaglutide

  • Active comparator
    Cagrilintide Dose 1

    Participants will receive once-weekly s.c injection of cagrilintide dose 1 for 68 weeks.

    Drug: Cagrilintide

  • Placebo comparator
    Placebo Dose 1

    Participants will receive once-weekly s.c injection of placebo matched to cagrilintide dose 1 and semaglutide dose 1 for 68 weeks.

    Drug: Placebo cagrilintide · Drug: Placebo semaglutide

  • Placebo comparator
    Placebo Dose 2

    Participants will receive once-weekly s.c injection of placebo matched to cagrilintide dose 2 and semaglutide dose 2 for 68 weeks.

    Drug: Placebo cagrilintide · Drug: Placebo semaglutide

Interventions

  • Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached.

  • Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached.

  • DrugPlacebo cagrilintide

    Participants will receive placebo matched to cagrilintide subcutaneously.

  • DrugPlacebo semaglutide

    Participants will receive placebo matched to semaglutide subcutaneously.

06

What researchers measure

Primary outcomes

  1. CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c)

    Measured in percentage-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

Secondary outcomes

  1. CagriSema versus cagrilintide: Change in HbA1c

    Measured in percentage-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  2. CagriSema versus cagrilintide: Relative change in body weight

    Measured in percentage.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  3. CagriSema (dose 1) versus semaglutide (dose 2): Change in HbA1c

    Measured in percentage-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  4. CagriSema versus semaglutide: Relative change in body weight

    Measured in percentage.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  5. Cagrilintide versus placebo: Change in HbA1c

    Measured in percentage-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  6. Cagrilintide versus placebo: Relative change in body weight

    Measured in percentage.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  7. CagriSema versus semaglutide: Achievement of greater than or equal to (>=) 10 percent (%) weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  8. CagriSema versus semaglutide: Achievement of >= 15 % weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  9. CagriSema versus semaglutide: Achievement of >= 20 % weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  10. CagriSema (pooled doses) versus semaglutide (pooled doses): Continuous Glucose Monitoring (CGM) - Change in Time in Range (TIR) 3.9-10.0 millimoles per litre (mmol/L) (70-180 milligrams per decilitre [mg/dL])

    Measured in percentage-points.

    Time frame: From baseline (week -3) to end of treatment (week 68)

  11. CagriSema versus semaglutide: CGM - Change in time in Tight Target Range (TITR) 3.9-7.8 (mmol/L) (70-140 mg/dL)

    Measured in percentage-points.

    Time frame: From baseline (week -3) to end of treatment (week 68)

  12. CagriSema versus semaglutide: Change in Systolic Blood Pressure (SBP)

    Measured in millimeters of mercury (mmHg).

    Time frame: From baseline (week 0) to end of treatment (week 68)

  13. CagriSema versus semaglutide: Ratio to baseline in triglycerides

    Measured as ratio of triglycerides.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  14. CagriSema versus semaglutide: Ratio to baseline in non-High Density Lipoprotein (HDL) cholesterols

    Measured as ratio of non-HDL cholesterol.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  15. CagriSema versus semaglutide: CGM - Change in Time In Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)

    Measured in percentage-points.

    Time frame: From baseline (week -3) to end of treatment (week 68)

  16. CagriSema versus semaglutide: Ratio to baseline in high sensitivity C-Reactive Protein (hsCRP)

    Measured as ratio of hsCRP.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  17. CagriSema versus semaglutide: Change in Fasting Plasma Glucose (FPG)

    Measured in mmol/L.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  18. CagriSema versus semaglutide: Achievement of HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])

    Measured as count of participants.

    Time frame: At end of treatment (week 68)

  19. CagriSema versus semaglutide: Achievement of HbA1c target values of less than or equal to (≤)6.5% (≤48 mmol/mol)

    Measured as count of participants.

    Time frame: At end of treatment (week 68)

  20. CagriSema versus semaglutide: CGM - Change in time above range, >10.0 mmol/L (>180 mg/dL)

    Measured in percentage-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  21. CagriSema versus semaglutide: CGM - Change in time above range, >13.9 mmol/L (>250 mg/dL)

    Measured in percentage-points.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  22. CagriSema versus semaglutide: CGM - Within-day glycaemic variability (% coefficient of variation [CV])

    Measured in percentage.

    Time frame: At end of treatment (week 68)

  23. CagriSema versus semaglutide: Achievement of ≥ 5 % weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  24. CagriSema versus semaglutide: Change in waist circumference

    Measured in centimetre.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  25. CagriSema versus semaglutide: Change in Diastolic Blood Pressure (DBP)

    Measured in mmHg.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  26. CagriSema versus semaglutide: Ratio to baseline in total cholesterol

    Measured as ratio of total cholesterol.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  27. CagriSema versus semaglutide: Ratio to baseline in HDL cholesterol

    Measured as ratio of HDL cholesterol.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  28. CagriSema versus semaglutide: Ratio to baseline in low-density lipoprotein (LDL) cholesterol

    Measured as ratio of LDL cholesterol.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  29. CagriSema versus semaglutide: Ratio to baseline in very low-density lipoprotein (VLDL) cholesterol

    Measured as ratio of VLDL.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  30. CagriSema versus semaglutide: Ratio to baseline in free fatty acids

    Measured as ratio of free fatty acids.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  31. CagriSema versus semaglutide: Change in Short Form (SF)-36v score- Physical component summary score

    SF-36v2 measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and an standard deviation of 10. Physical component summary score range from 6.1 to 79.7, with higher scores indicating better functional health and well-being.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  32. CagriSema versus semaglutide: Change in SF-36v2 score- Mental component summary score

    SF-36v2 measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and an standard deviation of 10. Mental component summary score range from -3.8 to 78.7, with higher scores indicating better functional health and well-being.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  33. CagriSema versus semaglutide: Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score

    DTSQc measures treatment satisfaction and diabetes-specific quality of life (QoL). The measure consists of 8 items yielding 1 global score and 2 single item scores. Total treatment satisfaction scores range from 0-36, with higher scores indicating greater satisfaction; the perceived frequency of hyperglycemia/hypoglycemia items are scored separately, with lower scores indicating better perceived blood glucose control.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  34. CagriSema versus semaglutide: Change in Treatment Related Impact Measure for Diabetes (TRIM-D) score

    TRIM-D measures impact of diabetes treatment. The measure consists of 28 items yielding 5 domain scores and a total score. The scores were transformed to a 0-100 scale with higher scores indicating a better health state.

    Time frame: From baseline (week 0) to end of treatment (week 68)

  35. CagriSema versus semaglutide, placebo and cagrilintide: Number of treatment emergent adverse events (TEAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 75)

  36. CagriSema versus semaglutide: Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (54 mg/dL), confirmed by BG meter)

    Measured as count of episodes.

    Time frame: From baseline (week 0) to end of study (week 75)

  37. CagriSema versus semaglutide: Number of severe hypoglycaemic episodes (level 3)

    Measured as count of episodes. Hypoglycaemia episodes (level 3) are the episodes associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold.

    Time frame: From baseline (week 0) to end of study (week 75)

07

Study locations

405 sites
  • Synexus Clin Res-Birmingham
    Birmingham, Alabama 35211, United States
  • Univ of Alabama_Birmingham
    Birmingham, Alabama 35294, United States
  • Cahaba Research
    Pelham, Alabama 35124, United States
  • Velocity Clinical Research-Phoenix
    Phoenix, Arizona 85006, United States
  • Synexus Rsch /Cnt Phnx Med C
    Phoenix, Arizona 85020, United States
  • Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
  • Velocity Clinical Res-Banning
    Banning, California 92220, United States
  • Velocity Clin Res-Chula Vista
    Chula Vista, California 91911, United States
  • John Muir Physicians Network
    Concord, California 94520, United States
  • Headlands Research California, LLC
    Escondido, California 92025, United States
  • Velocity Clin Res Gardena
    Gardena, California 90247, United States
  • Velocity Clin Res San Diego
    La Mesa, California 91942, United States
  • Loma Linda Univ Hlth Cr Endo
    Loma Linda, California 92354, United States
  • Facey Medical Foundation
    Mission Hills, California 91345, United States
  • Desert Oasis Hlthcr Med Group
    Palm Springs, California 92262, United States
  • Velocity Clin Res- San Bern
    San Bernardino, California 92408, United States
  • Linda Vista Health Care Ctr
    San Diego, California 92111, United States
  • Velocity Clin Res Santa Ana
    Santa Ana, California 92704, United States
  • Premier Medical Center, Inc.
    Toluca Lake, California 91602, United States
  • Velocity Clin Res - Panorama
    Van Nuys, California 91405, United States
  • Optumcare Clinical Trials,LLC-Golden
    Colorado Springs, Colorado 80906, United States
  • Northeast Research Institute
    Jacksonville, Florida 32204, United States
  • Clinical Trial Services Corp
    Miami, Florida 33144, United States
  • Bioclinical Research Alliance
    Miami, Florida 33155, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • South Broward Research LLC
    Miramar, Florida 33027, United States
  • West Orange Endocrinology
    Ocoee, Florida 34761, United States
  • Optimal Research Sites
    Orange City, Florida 32763, United States
  • Advent Health-Res Inst
    Orlando, Florida 32804, United States
  • AdventHealth Diab Inst
    Orlando, Florida 32804, United States
  • Synexus Clin Res - Orlando
    Orlando, Florida 32806, United States
  • Oviedo Medical Research, LLC
    Oviedo, Florida 32765, United States
  • Hope Clin Res & Wellness
    Conyers, Georgia 30094, United States
  • East Coast Institute for Res
    Macon, Georgia 31210, United States
  • Urban Family Practice Assoc
    Marietta, Georgia 30067, United States
  • Endocrine Research Solutions, Inc.
    Roswell, Georgia 30076, United States
  • Endocrine Research Solutions
    Roswell, Georgia 30076, United States
  • Pacific Diabetes & Endo Ctr
    Honolulu, Hawaii 96813, United States
  • St. Luke's Health System
    Boise, Idaho 83702, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Clinical Invest Special_Gurnee
    Gurnee, Illinois 60031, United States
  • Endeavor Health
    Skokie, Illinois 60077, United States
  • Evanston Premier Hlthcr Res
    Skokie, Illinois 60077, United States
  • Iowa Diabetes & Endo Res Ctr
    West Des Moines, Iowa 50266, United States
  • Alliance for Multispec Res
    Newton, Kansas 67114, United States
  • Cotton-O'Neil Diab & Endo Ctr
    Topeka, Kansas 66606, United States
  • Velocity Clin Res Lafayette
    Lafayette, Louisiana 70508, United States
  • BTC of New Bedford, LLC
    New Bedford, Massachusetts 02740, United States
  • Velocity Clin Res Gulfport
    Gulfport, Mississippi 39503, United States
  • Diabetes & Endo Specialists Inc
    Chesterfield, Missouri 63017, United States
  • Premier Research Inc.
    Trenton, New Jersey 08611, United States
  • Velocity Clin Res Albuquerque
    Albuquerque, New Mexico 87107, United States
  • AMC Community Endocrinology
    Albany, New York 12203, United States
  • Velocity Clin Res Syracuse
    East Syracuse, New York 13057, United States
  • Southgate Medical Group, LLP
    West Seneca, New York 14224, United States
  • Great Lakes Medical Research
    Westfield, New York 14787, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Carteret Medical Group
    Morehead City, North Carolina 28557, United States
  • Piedmont Healthcare/Research
    Statesville, North Carolina 28625, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • Synexus Clinical Research US, Inc
    Akron, Ohio 44311, United States
  • Centricity Research
    Columbus, Ohio 43213, United States
  • Alliance for Multispec Res
    Norman, Oklahoma 73069, United States
  • Clinical Res Collaborative
    Cumberland, Rhode Island 02864, United States
  • Velocity Clin Res Providence
    East Greenwich, Rhode Island 02818, United States
  • AnMed Health IMA
    Anderson, South Carolina 29621, United States
  • Synexus Clin Res US-Anderson
    Anderson, South Carolina 29621, United States
  • Velocity Clinical Res-Anderson
    Anderson, South Carolina 29621, United States
  • Velocity Clin Res Gaffney
    Gaffney, South Carolina 29340, United States
  • Hillcrest Clinical Research
    Simpsonville, South Carolina 29681-1538, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • Velocity Clin Res Spartanburg
    Spartanburg, South Carolina 29303, United States
  • Holston Medical Group Pc
    Bristol, Tennessee 37620-7352, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Clinical Research Associates
    Nashville, Tennessee 37203, United States
  • Arlington Family Res. Ctr Inc
    Arlington, Texas 76012-4637, United States
  • Velocity Clin Res Austin
    Austin, Texas 78759, United States
  • UT Health University of Texas
    Bellaire, Texas 77401, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • Synexus Clin Res Dallas
    Dallas, Texas 75234, United States
  • Cedar Health Research
    Dallas, Texas 75251, United States
  • JCCT- Juno NW Houston
    Houston, Texas 77040, United States
  • Synergy Groups Medical
    Houston, Texas 77061, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • Medical Colleagues-Texas LLP
    Katy, Texas 77450, United States
  • Sante Clinical Research
    Kerrville, Texas 78028, United States
  • Discovery MM Services, INC Missouri
    Missouri City, Texas 77459, United States
  • AES San Antonio
    San Antonio, Texas 78229, United States
  • University of Texas San Antonio
    San Antonio, Texas 78229, United States
  • NE Clin Res of San Antonio
    San Antonio, Texas 78233, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • DM Clin Rsrch/Fam Diag Clinic
    Tomball, Texas 77375, United States
  • Diabetes & Endo Treatment Spec
    Sandy City, Utah 84093, United States
  • Velocity Clin Res-Salt Lk City
    West Jordan, Utah 84088, United States
  • TPMG Clinical Research
    Newport News, Virginia 23606, United States
  • Rainier Clin Res Ctr Inc
    Renton, Washington 98057, United States
  • St. Vincent Hosp-Prevea Health
    Green Bay, Wisconsin 54303, United States

Showing the first 100 of 405 sites across 32 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Buse JB, Bajaj HS, Dalskov SM, Donaldson L, Hansen Duus HH, Fabricius TW, Haluzik M, Lingvay I, Pedersen SD, Pratley RE, Jain AB; REIMAGINE 2 study group. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026 Jun 7:S2213-8587(26)00125-7. doi: 10.1016/S2213-8587(26)00125-7. Online ahead of print. PubMed 42251859 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Nov 2025, 25 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 25 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2023
First posted
Oct 4, 2023
StartActual
Sep 27, 2023
Primary completionActual
Nov 19, 2025
CompletionActual
Jan 6, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06065540
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 4, 2023
Start date
Sep 27, 2023
Primary completion
Nov 19, 2025
Completion
Jan 6, 2026
Last update
Jul 8, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion